Pesquisar
Abivax SA
ABVXAdicionar à lista de desejos
87.580USD
-2.620-2.90%
Fechamento 11-13 16:00（ET）
7.64BValor de mercado
0.00P/L TTM
Sobre o Abivax SA Empresa
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA Perfil
Código da empresaABVX
Nome da EmpresaAbivax SA
Data de listagemJun 26, 2015
CEOde Garidel (Marc)
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscal- -
Endereço7-11 Boulevard Haussmann
CidadePARIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísFrance
Código postal75009
Telefone33153830963
Sitehttps://www.abivax.com/
Código da empresaABVX
Data de listagemJun 26, 2015
CEOde Garidel (Marc)
Executivos da empresa Abivax SA
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Ms. Jennifer Fine
Ms. Jennifer Fine
Senior Vice President, Global Head - HEOR and RWE
Senior Vice President, Global Head - HEOR and RWE
--
--
Mr. Kim Kelly
Mr. Kim Kelly
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Keith Fournier, Ph.D.
Dr. Keith Fournier, Ph.D.
Senior Vice President - Global Regulatory Affair
Senior Vice President - Global Regulatory Affair
--
--
Dr. Maurus de la Rosa, Ph.D.
Dr. Maurus de la Rosa, Ph.D.
Senior Vice President - Research
Senior Vice President - Research
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Kevin Shan, Ph.D.
Mr. Kevin Shan, Ph.D.
Vice President, Global Head - Biometrics
Vice President, Global Head - Biometrics
--
--
Dr. Dominik Hoechli, M.D.
Dr. Dominik Hoechli, M.D.
Independent Director
Independent Director
--
--
Ms. Nadege Briancon-Eris, Ph.D.
Ms. Nadege Briancon-Eris, Ph.D.
Senior Vice President, Global Head - Program Management
Senior Vice President, Global Head - Program Management
--
--
Ms. Mary Mantock
Ms. Mary Mantock
Senior Vice President, Global Head - Regulatory Affairs
Senior Vice President, Global Head - Regulatory Affairs
--
--
Ms. Hema Keshava
Ms. Hema Keshava
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Douglas Jacobstein, M.D.
Dr. Douglas Jacobstein, M.D.
Senior Vice President, Global Head - Clinical Development
Senior Vice President, Global Head - Clinical Development
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Abivax SA?
Os cinco principais acionistas de Abivax SA são: Mr. Pierre Courteille
Quantas instituições possuem ações da Abivax SA (ABVX)?
Em 2026Q1, 353 instituições possuíam ações da Abivax SA, com valor de mercado aproximado de 61.40M, representando 78.18% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -289711.00.